BRPI0417498A - método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular - Google Patents
método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascularInfo
- Publication number
- BRPI0417498A BRPI0417498A BRPI0417498-4A BRPI0417498A BRPI0417498A BR PI0417498 A BRPI0417498 A BR PI0417498A BR PI0417498 A BRPI0417498 A BR PI0417498A BR PI0417498 A BRPI0417498 A BR PI0417498A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- substituted
- suppressing
- treating
- subject
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title abstract 3
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- -1 4-piperazinyl Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N benzo-gamma-pyrone Natural products C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000893 fibroproliferative effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
MéTODO PARA SUPRIMIR UMA RESPOSTA IMUNE EM UM INDIVìDUO; MéTODO DE INIBIçãO DA PROLIFERAçãO DE UMA CéLULA; MéTODO DE TRATAMENTO DE UM DISTúRBIO PROLIFERATIVO EM UM INDIVìDUO; MéTODO PARA SELECIONAR UM AGENTE IMUNOSSUPRESSOR OU ANTI-PROLIFERATIVO; COMPOSIçãO FARMACéUTICA E ESTENTE VASCULAR. A presente invenção divulga métodos para a supressão de uma resposta imune em um sujeito, mediante tratamento de um neoplasma em um sujeito ou mediante tratamento de uma doença fibro-proliferativa vascular em um sujeito, o método incluindo a administração ao sujeito de uma quantidade terapeuticamente efetiva de um composto de 4H-1-benzopiran-4-ona substituído por 2- (4-piperazinila) ou um sal farmaceuticamente aceitável do mesmo, tendo a estrutura da Fórmula A, em que a presença de cada R~ 1~ e R~ 2~ é opcional e cada R~ 1~ e R~ 2~ são independentemente selecionados de alquila, alquila substituído, heteroalquila, cicloalquila substituído, heterocicloalquila, heterocicloalquila substituído, arila, arila substituído, heteroarila, heteroarila substituido, alcóxi, halogênio, hidróxi ou amino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52834003P | 2003-12-09 | 2003-12-09 | |
| PCT/US2004/041265 WO2005056014A1 (en) | 2003-12-09 | 2004-12-09 | Methods for suppressing an immune response or a treating a proliferative disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417498A true BRPI0417498A (pt) | 2007-05-29 |
Family
ID=34676839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417498-4A BRPI0417498A (pt) | 2003-12-09 | 2004-12-09 | método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8044057B2 (pt) |
| EP (1) | EP1694331B8 (pt) |
| JP (1) | JP2007513962A (pt) |
| KR (1) | KR20060123463A (pt) |
| CN (1) | CN1889958A (pt) |
| AT (1) | ATE447957T1 (pt) |
| AU (1) | AU2004296868B2 (pt) |
| BR (1) | BRPI0417498A (pt) |
| CA (1) | CA2546920A1 (pt) |
| DE (1) | DE602004024115D1 (pt) |
| IL (1) | IL176214A0 (pt) |
| MX (1) | MXPA06006651A (pt) |
| RU (1) | RU2006124421A (pt) |
| TR (2) | TR200604485T1 (pt) |
| WO (1) | WO2005056014A1 (pt) |
| ZA (1) | ZA200604724B (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| EP1886138A4 (en) * | 2005-05-11 | 2009-04-15 | Genetic Technologies Ltd | METHODS FOR ENRICHING FETAL CELLS |
| US8372851B2 (en) * | 2005-10-21 | 2013-02-12 | Exelixis, Inc. | Pyrazolo pyrimidines as casein kinase II (CK2) modulators |
| CU23511B6 (es) | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| EP1832289A3 (en) * | 2006-03-08 | 2007-12-12 | Sahajanand Medical Technologies PVT. ltd | Compositions and coatings for implantable medical devices |
| US20100130597A1 (en) * | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
| SI2396307T1 (sl) | 2009-02-11 | 2015-02-27 | Merck Patent Gmbh | Novi amino azaheterockliäśni karboksamidi |
| JP5763636B2 (ja) | 2009-08-07 | 2015-08-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規なアザ複素環化合物 |
| CN101849934B (zh) * | 2010-05-25 | 2011-11-09 | 苏州大学 | 一种磷脂酰肌醇-3-激酶抑制剂及其应用 |
| AU2011282684B2 (en) | 2010-07-29 | 2015-05-21 | Merck Patent Gmbh | Cyclic amine azaheterocyclic carboxamides |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| LT2643313T (lt) | 2010-11-24 | 2016-10-25 | Merck Patent Gmbh | Chinazolino karboksamido azetidinai |
| UY34013A (es) | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ?compuestos de cromenona con actividad anti-tumoral?. |
| PH12013502240B1 (en) | 2011-05-04 | 2018-06-27 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinase |
| US9321760B2 (en) | 2011-09-12 | 2016-04-26 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| PT2755965T (pt) | 2011-09-12 | 2017-11-02 | Merck Patent Gmbh | Novas imidazol aminas como moduladores da atividade quinase |
| EA027968B1 (ru) | 2011-12-22 | 2017-09-29 | Мерк Патент Гмбх | Гетероциклические карбоксамиды в качестве модуляторов активности киназ |
| CA2866021C (en) * | 2012-03-06 | 2020-09-22 | The Board Of Trustees Of The University Of Illinois | Procaspace 3 activation by pac-1 combination therapy |
| US9580443B2 (en) | 2012-11-16 | 2017-02-28 | Merck Patent Gmbh | Heterocyclic derivatives as modulators of kinase activity |
| EP2920154B1 (en) | 2012-11-16 | 2017-10-11 | Merck Patent GmbH | Novel imidazol-piperidinyl derivatives as modulators of kinase activity |
| NZ706418A (en) | 2012-11-29 | 2019-09-27 | Merck Patent Gmbh | Azaquinazoline carboxamide derivatives |
| US9763950B2 (en) | 2013-03-04 | 2017-09-19 | Astrazeneca Ab | Combination treatment |
| AR095202A1 (es) | 2013-03-11 | 2015-09-30 | Merck Patent Gmbh | Heterociclos como moduladores de la actividad quinasa |
| EP3125935B1 (en) | 2014-04-03 | 2019-10-23 | Merck Patent GmbH | Combinations of cancer therapeutics |
| CN108929329B (zh) * | 2017-05-24 | 2020-12-11 | 中国医学科学院药物研究所 | 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物 |
| CN107641109B (zh) * | 2017-10-16 | 2019-05-24 | 厦门大学 | 一种类黄酮化合物及其制备方法和应用 |
| CN107602520B (zh) * | 2017-10-16 | 2019-06-14 | 厦门大学 | 一种含哌嗪环的类异黄酮化合物及其制备方法和应用 |
| AU2018368453B2 (en) | 2017-11-17 | 2024-05-30 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
| CA3114385A1 (en) | 2018-10-05 | 2020-04-09 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2022101459A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (pt) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| AU634994B2 (en) | 1988-12-21 | 1993-03-11 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US5703075A (en) * | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US20030050692A1 (en) * | 2000-12-22 | 2003-03-13 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
-
2004
- 2004-12-09 AT AT04813574T patent/ATE447957T1/de not_active IP Right Cessation
- 2004-12-09 KR KR1020067013786A patent/KR20060123463A/ko not_active Withdrawn
- 2004-12-09 CA CA002546920A patent/CA2546920A1/en not_active Abandoned
- 2004-12-09 MX MXPA06006651A patent/MXPA06006651A/es unknown
- 2004-12-09 WO PCT/US2004/041265 patent/WO2005056014A1/en not_active Ceased
- 2004-12-09 DE DE602004024115T patent/DE602004024115D1/de not_active Expired - Lifetime
- 2004-12-09 EP EP04813574A patent/EP1694331B8/en not_active Expired - Lifetime
- 2004-12-09 TR TR2006/04485T patent/TR200604485T1/xx unknown
- 2004-12-09 CN CNA2004800366652A patent/CN1889958A/zh active Pending
- 2004-12-09 RU RU2006124421/15A patent/RU2006124421A/ru unknown
- 2004-12-09 AU AU2004296868A patent/AU2004296868B2/en not_active Ceased
- 2004-12-09 TR TR2008/08208T patent/TR200808208T1/xx unknown
- 2004-12-09 JP JP2006543983A patent/JP2007513962A/ja active Pending
- 2004-12-09 BR BRPI0417498-4A patent/BRPI0417498A/pt not_active IP Right Cessation
- 2004-12-09 US US10/581,257 patent/US8044057B2/en not_active Expired - Fee Related
-
2006
- 2006-06-08 ZA ZA200604724A patent/ZA200604724B/xx unknown
- 2006-06-08 IL IL176214A patent/IL176214A0/en unknown
-
2011
- 2011-09-22 US US13/241,008 patent/US20120039903A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004024115D1 (de) | 2009-12-24 |
| TR200808208T1 (tr) | 2008-12-22 |
| ZA200604724B (en) | 2010-01-27 |
| MXPA06006651A (es) | 2006-08-11 |
| US8044057B2 (en) | 2011-10-25 |
| CA2546920A1 (en) | 2005-06-23 |
| EP1694331B1 (en) | 2009-11-11 |
| IL176214A0 (en) | 2006-10-05 |
| EP1694331B8 (en) | 2010-02-24 |
| WO2005056014A8 (en) | 2006-08-31 |
| KR20060123463A (ko) | 2006-12-01 |
| WO2005056014A1 (en) | 2005-06-23 |
| RU2006124421A (ru) | 2008-01-20 |
| US20070173514A1 (en) | 2007-07-26 |
| ATE447957T1 (de) | 2009-11-15 |
| AU2004296868A1 (en) | 2005-06-23 |
| US20120039903A1 (en) | 2012-02-16 |
| CN1889958A (zh) | 2007-01-03 |
| JP2007513962A (ja) | 2007-05-31 |
| TR200604485T1 (tr) | 2007-01-22 |
| AU2004296868B2 (en) | 2010-11-25 |
| EP1694331A1 (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417498A (pt) | método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| EP4548918A3 (en) | Tricyclic compounds as inhibitors of kras | |
| BR0312934A (pt) | Derivados de 8-hidróxi quinolina | |
| TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| MXPA04012965A (es) | Inhibidores virales. | |
| EP1539234A4 (en) | METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS | |
| BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
| CY1109245T1 (el) | Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα | |
| CR20240261A (es) | Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos | |
| DE60237993D1 (de) | Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs | |
| PT1562954E (pt) | Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a. | |
| NO20034301L (no) | Cyano-substituerte dihydropyrimidin forbindelser | |
| SA523440403B1 (ar) | Magl مثبط | |
| EA200870454A1 (ru) | Способ ингибирования c-kit киназы | |
| TW200742580A (en) | Methods for treating nephrolithiasis | |
| NO20076075L (no) | 4-anilino-3-kinolinkarbonitriler for behandling av cancer | |
| BR0209985A (pt) | Composto e método para o tratamento de um paciente | |
| GEAP202416568A (en) | Triazolone derivative salt as neutrophil elastase inhibitor | |
| BR0015121A (pt) | Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação | |
| BR0214293A (pt) | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo | |
| TR202108754A2 (tr) | Covid-19 tedavi̇si̇ i̇çi̇n ti̇azoli̇di̇nedi̇on bi̇leşi̇ği̇ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |